Investors

 

Key to long-term value: discipline, execution and consistent communication.

Print pageEmail pageRSS feedsShare page

News releases

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct, or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Keyword Search
 
2016 | 2015 | 2014 | 2013
DateTitle 
09/15/16ARIAD Announces Ponatinib Data Presentations at European School of Haematology Annual John Goldman Conference on Chronic Myeloid Leukemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 15, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced several data presentations on Iclusig® (ponatinib) that will take place at the 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy being held in Houston, September 15 to 18, 2016. A total of eight abstracts will be presented, including two oral presentations. The schedule and abstract information are listed... 
Printer Friendly Version
08/30/16ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.S. Food and Drug Administration (FDA). ARIAD is seeking U.S. marketing approval of brigatinib for patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) w... 
Printer Friendly Version
08/29/16ARIAD to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 29, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Morgan Stanley Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Monday, September 12, 2016 at 2:50 p.m. (ET). The ARIAD presentation will be webcast live and can be accessed by ... 
Printer Friendly Version
07/28/16ARIAD Reports Second Quarter and First Half 2016 Financial Results
~Product revenue of $65.3 million for Q2 2016, including one-time $25.5 million from France ~U.S. product revenue of $32.6 million for Q2 2016, representing 50% growth from prior year ~Conference call scheduled today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 28, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter and first half of 2016, including revenue... 
Printer Friendly Version
07/05/16ARIAD to Webcast Conference Call on Second Quarter 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 5, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2016 financial results on Thursday, July 28, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by vis... 
Printer Friendly Version
06/24/16ARIAD Announces Webcast of Its Annual Stockholders Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on July 21, 2016 and can be accessed by visiting the investor relations section of the Company’s website at: http://www.ariad.com/investor. The annual meeting will take place at 10:00 a.m. (EDT) at the Company’s offices in Cambridge, Massachusetts and will include an over... 
Printer Friendly Version
06/17/16ARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North Africa
~ ARIAD to Receive More Than 50 Percent of Iclusig Sales in These Regions ~ Agreements Include Buy-Back Provisions in Case of a Change in Control of ARIAD CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2016-- ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ:ARIA) today announced that it has completed two distribution agreements for Iclusig® (ponatinib) outside of the United States. In Latin America, ARIAD and Pint Pharma International S.... 
Printer Friendly Version
06/17/16ARIAD Initiates Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration Ahead of Plan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the initiation of a New Drug Application (NDA) submission for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.S. Food and Drug Administration (FDA). ARIAD is seeking U.S. marketing approval of brigatinib for patients with ALK+ non-small cell lung cancer (NSCLC) who are resistant to crizotinib. Brigatinib... 
Printer Friendly Version
06/17/16ARIAD Completes Strategic Review and Announces Plans for Growth
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the completion of its strategic review and its plans for future growth and vision to become a leader in the discovery, development and commercialization of precision therapies for patients with rare cancers. ARIAD detailed its new strategy for growth and increased patient and shareholder value, and provided an update on its continued progre... 
Printer Friendly Version
06/13/16ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 PACE Clinical Trial
~ 82 Percent of CP-CML Patients Who Achieved MCyR are Estimated to Remain in MCyR at Four Years ~ Overall Survival at Four Years is Estimated to be 77 Percent COPENHAGEN, Denmark & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 13, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow-up data from its pivotal Phase 2 PACE clinical trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated ... 
Printer Friendly Version
06/08/16ARIAD to Host Analyst & Investor Day in New York City
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.m. (EDT) in New York City. Paris Panayiotopoulos, president and chief executive officer of ARIAD, will host the event along with other key members of ARIAD senior management. The meeting will focus on ARIAD’s co... 
Printer Friendly Version
06/06/16ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate and 12.9-Month Median Progression-Free Survival in ALTA Study
~ 67 Percent Confirmed Intracranial Objective Response Rate in Patients with Measurable Brain Metastases ~ Data from Pivotal Study in Refractory ALK Positive Non-Small Cell Lung Cancer Patients ~ Investor and Analyst Webcast to be Held at the 2016 ASCO Meeting Today at 7 a.m. CT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on bri... 
Printer Friendly Version
06/04/16ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations
~Brigatinib Achieves Confirmed Response in Patient with G1202R Mutation that Emerges Following Treatment with Current Approved Therapies CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced clinical data from an analysis aimed at characterizing the activity of its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase positiv... 
Printer Friendly Version
06/04/16ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients
~ Longest Time on Treatment Now More Than 3.5 Years for Patients with ALK+ Non-Small Cell Lung Cancer ~ Data from Phase 1/2 Clinical Trial Presented at 2016 ASCO Meeting CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase-positive (AL... 
Printer Friendly Version
06/02/16ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig®
~Divestiture to Incyte Strengthens Financial Position ~ ARIAD Receives $140 Million Upfront Payment, $135 million to be Received in Potential Oncology Milestones, Tiered Royalty Payments of Between 32% and 50% CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 2, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has completed the sale of its European operations to Incyte Corporation and entered into the previously a... 
Printer Friendly Version
06/01/16ARIAD to Present at the Jefferies 2016 Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Wednesday, June 8, 2016 at 11:00 a.m. (ET). The ARIAD presentation will be webcast live and can be accessed by ... 
Printer Friendly Version
05/31/16ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR and HER2, in Patients with Non-Small Cell Lung Cancer
AP32788 Designed to Address Unmet Need in Approximately 6,000 U.S. Patients with No Approved Targeted Treatment for EGFR Exon 20 or HER2 Point Mutations CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 31, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell ... 
Printer Friendly Version
05/24/16ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Jennifer L. Herron as executive vice president, chief commercial officer, effective May 31, 2016. She will report to ARIAD’s president and chief executive officer, Paris Panayiotopoulos. Ms. Herron will succeed Martin J. Duvall, who has made significant contributions to ARIAD since first joining the company in 2011. Mr. D... 
Printer Friendly Version
05/19/16ARIAD Announces Pricing and Reimbursement for Iclusig in France
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 19, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that negotiations with the Economic Committee on Health Care Products in France regarding pricing and reimbursement for Iclusig® (ponatinib) have now concluded. As a result, ARIAD will record net product revenue related to cumulative shipments in France of approximately $25 million in the second quarter of 2016. Iclusig has b... 
Printer Friendly Version
05/18/16ARIAD Announces Data Presentations at the 2016 ASCO Annual Meeting
~Oral Presentation of Clinical Data from ALTA Pivotal Trial on Monday, June 6, 2016 ~ ASCO Presentation to Include Approximately 3 Months of Additional Follow-up Compared to Abstract ~Investor and Analyst Briefing to be Held at ASCO on Monday, June 6 at 7 a.m. CT CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on brigatinib, its invest... 
Printer Friendly Version
05/10/16ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review
~Recorded Net Product Revenue of $33.6 million for the first quarter of 2016; growth of 41% from prior year ~Provides guidance for 2016, including strengthened year-end cash position, following announced Incyte transaction: Global product and royalty revenue of $170 million to $180 million R&D expense of $175 million to $180 million SG&A expense of $120 million to $125 million ... 
Printer Friendly Version
05/09/16Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
Incyte to Accelerate the Expansion of its European Organization to Optimize the Potential of Future Product Launches in Europe ARIAD to Receive $140 Million Upfront Payment, Plus Tiered Royalties on European Sales of Iclusig and Potential Milestones on Future Indications for Iclusig WILMINGTON, Del. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2016-- Incyte Corporation (Nasdaq:INCY) and ARIAD Pharmaceuticals... 
Printer Friendly Version
04/26/16ARIAD to Webcast Conference Call on First Quarter 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2016 financial results on Tuesday, May 10, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by visit... 
Printer Friendly Version
04/19/16ARIAD Announces Results of Preclinical Studies on AP32788 at the Annual Meeting of the American Association for Cancer Research
First Presentation of Preclinical Data Supports Upcoming Clinical Testing in Non-Small Cell Lung Cancer Patients with EGFR and HER2 Exon 20 Mutations CAMBRIDGE, Mass. & NEW ORLEANS--(BUSINESS WIRE)--Apr. 19, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of comprehensive preclinical studies on its investigational tyrosine kinase inhibitor (TKI), AP32788, at the American Association for Cancer Research ... 
Printer Friendly Version
04/15/16ARIAD Presents Updated Phase 1/2 Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer
GENEVA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 15, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib, in patients with advanced malignancies, including anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC), from an ongoing Phase 1/2 trial. This report includes updated data on the brigatinib safety profile and pharmacokin... 
Printer Friendly Version
04/11/16ARIAD Announces Initiation of Randomized, First-Line Phase 3 Trial of Brigatinib in Treatment of ALK-Positive Non-Small Cell Lung Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 11, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the initiation of a randomized, first-line Phase 3 clinical trial of brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, in adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitor. The ALTA 1L (ALK in Lung Can... 
Printer Friendly Version
03/29/16ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review
Approximately 25 Percent of its Headquarter Positions to be Impacted CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 29, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is reducing approximately 25 percent of its headquarter positions. The reduction includes approximately 90 positions in the U.S. and Europe. No customer-facing positions within ARIAD’s commercial or medical affairs organizations are included in this action. ... 
Printer Friendly Version
03/22/16ARIAD Reports Inducement Grant to New Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 22, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported the grant of an inducement award to its new Chief Financial Officer, Manmeet S. Soni. The award was approved by the Compensation Committee and ratified by the full Board of Directors on March 8, 2016, as an inducement material to Mr. Soni’s entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). The awar... 
Printer Friendly Version
03/11/16ARIAD Announces Appointment of Manmeet S. Soni as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Manmeet S. Soni, 38, as executive vice president, chief financial officer and treasurer, effective March 21, 2016. He will report to Paris Panayiotopoulos, president and chief executive officer of ARIAD. Mr. Soni will succeed Edward M. Fitzgerald, who has made significant contributions to the company as ARIAD’s chief fin... 
Printer Friendly Version
02/29/16ARIAD to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 29, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business at two upcoming investor conferences: The Cowen and Company 36th Annual Health Care Conference being held in Boston on Wednesday, March 9, at 8:40 a.m. (ET) The Barclays Global Healthca... 
Printer Friendly Version
02/23/16ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress
Iclusig Net Product Revenue Guidance for 2016 in the Range of $190 Million to $200 Million Filing for U.S. Marketing Approval of Brigatinib Expected This Year Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 23, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2015 and issued 2016 product reven... 
Printer Friendly Version
02/10/16ARIAD to Present at the RBC Capital Markets Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Wednesday, February 24, at 4:35 p.m. (ET). The ARIAD presentation at the RBC Capital Markets Healthcare Conference ... 
Printer Friendly Version
02/02/16ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its fourth quarter and year-end 2015 financial results on Tuesday, February 23, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast... 
Printer Friendly Version
02/01/16ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788
Internally Discovered Product Candidate Designed to Address Unmet Need in Non-Small Cell Lung Cancer Patients with Specific EGFR and HER2 Kinase Mutations CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AP32788, a tyrosine kinase inhibitor (T... 
Printer Friendly Version
01/15/16ARIAD Reports Inducement Grant to New Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 15, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported the grant of an inducement award to its new Chief Executive Officer, Paris Panayiotopoulos. The award was approved by the Compensation Committee and ratified by the full Board of Directors on December 16, 2015, as an inducement material to Mr. Panayiotopoulos’ entering into employment with the Company in accordance with NASDAQ Listing Rule ... 
Printer Friendly Version
01/11/16ARIAD Announces Termination of Shareholder Rights Plan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that its Board of Directors has unanimously approved the termination of the Company’s Section 382 Rights Agreement, or the Rights Plan, originally adopted on October 31, 2013, effective immediately. The Rights Plan and the associated rights expired at 5:00 p.m. EST on January 8, 2016, and will be of no further force or effect. ARIAD shareho... 
Printer Friendly Version
01/10/16ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the election of Alexander J. Denner, Ph.D., as chairman of its board of directors in a unanimous vote effective January 8, 2016. Dr. Denner joined the ARIAD Board of Directors in February 2014 and most recently led the Board’s search committee to select the Company’s new CEO Paris Panayiotopoulos. This Smart News Release features multime... 
Printer Friendly Version
01/08/16ARIAD and Otsuka Submit New Drug Application in Japan for Ponatinib
Submission based on Phase 2 trial in Japanese patients with refractory chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a new drug application (NDA) to the Japanese Pharmaceuticals and Medical Devices A... 
Printer Friendly Version